Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: enibarcimab | 0.81 |
| trials ClinicalTrials.gov | 462 Parkinson's trials, 3 stopped | 0.95 |
| literature PubMed | 20 Parkinson's papers of 7,427 | 0.60 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 6476
Sealed predictions
- ADM in dopamine neurons, braak-0.08 (p 0.838) → -0.22 (p 0.576)receipt 6484
Swarm cases
receipt 6484: ADM in dopamine neurons, braak
- power
- full sample -0.16 (p 0.538, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.355, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.355, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.06, sign flips 0; without severely affected donors -0.16 (p 0.538, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ADM in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts